Características
Se ha publicado convocatoria transnacional conjunta del partenariado European Partnership for Personalised Medicine (EP PerMed), Joint Transnational Call (JTC) 2026 Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026)
En esta convocatoria se financiarán proyectos de investigación en salud humana sobre estrategias innovadoras de medicina personalizada para pacientes con enfermedades cardiovasculares, metabólicas o renales. Los proyectos de investigación podrán centrarse en una única enfermedad o abordar estas condiciones de manera combinada.
Se valorarán positivamente los proyectos de investigación que combinen un enfoque de medicina personalizada con care strategies dirigidas a vías biológicas compartidas o a mecanismos subyacentes comunes de las enfermedades cardiovasculares, metabólicas y renales.
La convocatoria está cofinanciada por la Unión Europea y cuenta con la participación de 39 organizaciones financiadoras de 27 países, con un presupuesto total estimado superior a 38 millones de euros.
Asimismo, en esta convocatoria participa como organismo financiador nacional, el Instituto de Salud Carlos III (ISCIII).
Requisitos
Proposals should address one or more of the following aspects:
- Development and validation of innovative personalised therapeutic approaches for cardiovascular, metabolic or kidney diseases through testing in relevant pre-clinical models (e.g., human cell cultures, organoids, organs-on-chips, disease-specific animal models, or in silico models).
- Identification and validation of molecular markers/signatures or cutting-edge technologies (see also point 2 below) to monitor treatment response in patients with cardiovascular, metabolic or kidney diseases in order to tailor treatment pathways. This may include the analysis of the treatment effectiveness or treatment-related (including multi-medication) adverse effects as well as dose optimisation.
- Identification and validation of stratifying molecular markers/signatures or stratifying diagnostic technologies for early disease risk prediction and prevention of disease worsening or comorbidities in patients with cardiovascular, metabolic or kidney diseases, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.
Research projects that combine a personalised medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular, metabolic and kidney diseases are welcome.
Projects funded under this call are furthermore required to include a dedicated work package focussing on the question of the translation or implementation of the research outcomes into clinical practice with a focus on e.g. patient outcome, patient preferences, costs, reimbursement, education (to healthcare providers, patients and citizens), ELSA (ethical, legal and societal aspect) or accessibility at the point of care.
Plazo de presentación.
En la siguiente table se detallan las diferentes fechas:
| Phase | Date |
|---|---|
| Call opens | November 25, 2025 |
| Deadline pre-proposals | February 10, 2026, (14:00 CET) |
| Notification of the results of the pre-proposal | May 5, 2026 |
| Deadline fullproposals | June 9, 2026, (14:00 CET) |
| Rebuttal stage | Mid/end of August, 2026 |
| Communication of the funding decisions | October 2026 |